曹芝艳;于泓;

• 1:遵义医科大学附属医院

摘要(Abstract)：

类风湿关节炎(RA)是一种病因不明的全身性免疫性炎症,主要损伤关节滑膜,导致关节畸形和功能丧失,其药物治疗包括传统抗风湿药物、生物制剂及各种生物仿制药。传统抗风湿药如甲氨蝶呤、来氟米特和糖皮质激素等是RA治疗的基础用药。生物制剂是一种更直接、更明确、更有针对性的治疗方法,可延缓RA疾病进展,目前可供临床选择的生物制剂包括肿瘤坏死因子抑制剂、IL-1受体拮抗剂、IL-6受体拮抗剂、B细胞耗竭剂、T细胞靶向药物及JAK激酶抑制剂等,分别具有不同的病理生理靶点。生物仿制药与生物制剂疗效相似,但经济成本更低,各种生物仿制药如基于单克隆抗体英夫利昔单抗、CT-P13(Inflectra)、SB2(Renflexis)等已陆续获得批准上市。干细胞移植因其免疫调节特性成为RA治疗的一种可用的替代方法,大量研究已证明其有效性及安全性。

关键词(KeyWords)： 类风湿性关节炎;药物疗法;干细胞移植

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 曹芝艳;于泓;

参考文献(References)：

• [1]Blair HA,Deeks ED. Abatacept:a review in rheumatoid arthritis[J]. Drugs,2017,77(11):1221-1233.
• [2]Littlejohn EA,Monrad SU. Early diagnosis and treatment of rheumatoid arthritis[J]. Prim CARE RESP J,2018,45(2):237-255.
• [3]Smolen JS,LandewéR,Bijlsma J,et al. EULAR recommendations for the manag ement of rheumatoid arthritis with synthetic and biological diseasemodifying antirhe umatic drugs:2016 update[J].Ann Rheum Dis,2017,76(6):960-977.
• [4]Reddy D,Trost LW,Lee T,et al. Rheumatoid arthritis:current pharmacologic treatment and anesthetic considerations[J]. Middle East J Anaesthesiol,2007,19(2):311-333.
• [5]Mann DL. Innate immunity and the failing heart:the cytokine hypothesis revisited[J]. Circ Res,2015,116(7):1254-1268.
• [6]Calabrese LH,Rose John S. IL-6 biology:implications for clinical targeting in r heumatic disease[J]. Nat Rev Rheumatol,2014,10(12):720-727.
• [7] Rubbert Roth A,Atzeni F,Masala IF,et al. TNF inhibitors in rheumatoid arthritis and spondyloarthritis:are they the same(Review)[J]. Autoimmun Rev,2018,17(1):24-28.
• [8]Hunter CA,Jones SA. IL-6 as a keystone cytokine in health and disease[J]. Nat Immunol,2015,16(5):448-457.
• [9]Romano C,Del Mastro A,Sellitto A,et al. Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients[J]. Clin Rheumatol,2018,37(6):1695-1700.
• [10]Xie F,Yun H,Bernatsky S,et al. Brief report:risk of gastrointestinal perforati on among rheumatoid arthritis patients receiving tofacitinib,tocilizumab,or other biologic treatments[J]. Arthritis Rheumatol,2016,68(11):2612-2617.
• [11] Pelechas E,Voulgari PV,Drossos AA. Sirukumab:a promising therapy for rheumatoid arthritis[J]. Expert Opin Biol Ther,2017,17(6):755-763.
• [12]Bakker SH,van der Gaag NA,de Ruiter GCW,et al. Selective intradural dorsal rhizotomy for persistent radicular leg pain:a contemporary series[J]. Spine J,2019,19(2):306-313.
• [13] Mok CC. Rituximab for the treatment of rheumatoid arthritis:an update[J]. Drug Des Devel Ther,2013,27(8):87-100.
• [14]Andersson AK,Li C,Brennan FM. Recent developments in the immunobiology of rheumatoid arthritis[J]. Arthritis Res Ther,2008,10(2):204-209.
• [15] Fernández-Díaz C,Loricera J,Casta eda S,et al. Abatacept in patients with rheu-m atoid arthritis and interstitial lung disease:A national multicenter study of 63 patients[J]. Semin Arthritis Rheum,2018,48(1):22-27.
• [16]Thakkar M,Bhuniya D,Kaduskar R,et al. Discovery and evaluation of 1H-pyrrolo[2,3-b] pyridine based selective and reversible small molecule BTK inhibitors for the treatment of rheumatoid arthritis[J]. Bioorg Med Chem Lett,2017,27(8):1867-1873.
• [17]Genovese MC,SmolenJS,Weinblatt ME,et al. Efficacy and safety of ABT 494,a selective JAK-1 inhibitor,in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate[J]. Arthritis Rheumatol,2016,68(12):2857-2866.
• [18]Taylor PC. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis[J]. Rheumatology,2019,58(1):17-26.
• [19]Chantal L. Clinical-scale expansion of mesenchymal stromal cells:a large bankin g experience[J]. J Transl Med,2016,14(1):145.
• [20] Mahajan TD,Mikuls TR. Recent advances in the treatment of rheumatoid arthritis[J]. Curr Opin Rheumatol,2018,30(3):231-237.
• [21]Braun J,Kay J. The safety of emerging biosimilar drugs for the treatment of rheu matoid arthritis[J]. Expert Opin Drug Saf,2017,16(3):289-302.
• [22]Boissier MC,Assier E,Biton J,et al. Regulatory T cells(Treg)in rheumatoid arthri tis[J]. Joint Bone Spine,2009,76(1):10-14.
• [23]Kohno Y,Mizuno M,Ozeki N,et al. Yields and chondrogenic potential of primary synovial mesenchymal stem cells are comparable between rheumatoid arthritis and ost eoarthritis patients[J]. Stem Cell Res Ther,2017,8(1):115.
• [24] Abdelmawgoud H,Saleh A. Anti-inflammatory and antioxidant effects of mesen chymal and hematopoietic stem cells in a rheumatoid arthritis rat model[J]. Adv Clin Exp Med,2018,27(7):873-880.
• [25]Jung SY. Adult stem cell treatment for rheumatoid arthritis[J]. J Rhetic Diseases,2018,25(3):158-168.
• [26]唐福林.北京协和医院自体外周血造血干细胞移植治疗顽固性类风湿关节取得近期疗效[J].中华医学信息导报,2001,16(22):10.
• [27]张效北,李江涛,赵和泰,等.间充质干细胞治疗类风湿性关节炎患者临床分析[J].中国现代医生,2011,49(34):139-140.
• [28]杜鸿昱,周敏,张素仙.脐带间充质干细胞治疗类风湿关节炎八例临床分析[J].云南医药,2014,35(3):359-361.
• [29]Jung SY. Adult stem cell treatment for rheumatoid arthritis[J]. J Rheumatic Dis,2018,25(3):158-168.